Allogene Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)

ALLO Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001737287 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$614.97M
345,490,881 shares Covers every share class this company has on file.
Insiders on file
8
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$23.73M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
3.86%
insider-held value divided by market capitalisation

What Allogene Therapeutics, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$0
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$190.89M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
150
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Allogene Therapeutics, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against Allogene Therapeutics, Inc..
Insider Reported role Shares Value Last action
Officers 2
Zachary Roberts EVP 581,166 $1.14M S Open-market sale Feb 2, 2026 position reported
Earl Martin Douglas General Counsel 564,948 $1.11M S Open-market sale Aug 21, 2026 position reported
Officers who also sit on the board 3
David D Chang CEO 6,351,707 $12.51M S Open-market sale Mar 16, 2026 position reported
Geoffrey M Parker Geoffrey M Parker CFO 1,252,795 $2.47M S Open-market sale Feb 2, 2026 position reported
Timothy L. Moore CTO 250,713 $493.9K S Open-market sale Feb 3, 2025 position reported
Directors 3
Arie Belldegrun Board Member 2,776,683 $5.47M A Grant or award Jan 24, 2025 position reported
Vicki L. Sato Board Member 162,575 $320.3K A Grant or award Jun 5, 2024 position reported
Deborah M. Messemer Board Member 107,431 $211.6K S Open-market sale Jun 10, 2025 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Allogene Therapeutics, Inc. (ALLO) filed a Form 8-K under Item 5.02 (directors and officers) on Sep 2, 2026

Director or officer change filing

The company filed a current report that includes Item 5.02, the item used to report departures, elections or appointments of directors and certain officers, and related pay arrangements. We record only that this filing exists: we have not extracted who left, who joined or whose role changed. Open the filing to read it.

Form 8-K filed Sep 2, 2026, item 5.02. SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 33 rows we hold, 1 are open-market purchases (P) and 19 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Allogene Therapeutics, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Aug 21, 2026 Earl Martin Douglas S Open-market sale 29,697 $2.12 $63.0K SEC filing ↗
Mar 16, 2026 David D Chang S Open-market sale 47,763 $2.47 $118.0K SEC filing ↗
Feb 2, 2026 Zachary Roberts S Open-market sale 35,700 $1.77 $63.2K SEC filing ↗
Feb 2, 2026 Earl Martin Douglas S Open-market sale 22,900 $1.76 $40.3K SEC filing ↗
Feb 2, 2026 David D Chang S Open-market sale 95,269 $1.80 $171.5K SEC filing ↗
Feb 2, 2026 Geoffrey M Parker S Open-market sale 24,001 $1.76 $42.2K SEC filing ↗
Jan 21, 2026 Zachary Roberts S Open-market sale 26,269 $1.56 $41.0K SEC filing ↗
Oct 21, 2025 Geoffrey M Parker S Open-market sale 36,744 $1.26 $46.3K SEC filing ↗
Jun 10, 2025 Deborah M. Messemer S Open-market sale 36,885 $1.42 $52.4K SEC filing ↗
Mar 14, 2025 David D Chang S Open-market sale 46,668 $1.96 $91.5K SEC filing ↗
Feb 18, 2025 Deborah M. Messemer S Open-market sale 13,313 $2.43 $32.4K SEC filing ↗
Feb 3, 2025 Zachary Roberts S Open-market sale 18,832 $1.70 $32.0K SEC filing ↗
Feb 3, 2025 Timothy L. Moore S Open-market sale 14,746 $1.71 $25.2K SEC filing ↗
Feb 3, 2025 Earl Martin Douglas S Open-market sale 6,404 $1.71 $11.0K SEC filing ↗
Feb 3, 2025 David D Chang S Open-market sale 46,003 $1.68 $77.3K SEC filing ↗
Feb 3, 2025 Geoffrey M Parker S Open-market sale 4,361 $1.73 $7.5K SEC filing ↗
Jan 24, 2025 Zachary Roberts A Grant or award 173,913 $0.00 $0 SEC filing ↗
Jan 24, 2025 Earl Martin Douglas A Grant or award 144,928 $0.00 $0 SEC filing ↗
Jan 24, 2025 David D Chang A Grant or award 552,174 $0.00 $0 SEC filing ↗
Jan 24, 2025 Geoffrey M Parker A Grant or award 173,913 $0.00 $0 SEC filing ↗
Jan 24, 2025 Arie Belldegrun A Grant or award 369,957 $0.00 $0 SEC filing ↗
Jan 21, 2025 Zachary Roberts S Open-market sale 27,199 $1.78 $48.4K SEC filing ↗
Dec 9, 2024 Deborah M. Messemer S Open-market sale 9,136 $2.18 $19.9K SEC filing ↗
Oct 21, 2024 Geoffrey M Parker F Shares withheld for taxes 36,404 $2.84 $103.4K SEC filing ↗
Aug 21, 2024 Earl Martin Douglas F Shares withheld for taxes 28,310 $2.79 $79.0K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Allogene Therapeutics, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Allogene Therapeutics, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.